UK NHS does not fund stem cell therapy for UC. Private insurance policies typically exclude stem cell treatments as unproven or experimental. International coverage is sporadic; some continental European policies may reimburse under compassionate-care exceptions, but this is inconsistent and requires pre-approval. Patients are generally responsible for all costs. Clarification with insurers before proceeding is essential.
UC-targeted stem cell infusions are offered in South Korea, Turkey, and select European centres at costs ranging from €3,500–€8,000 per course. UK private clinics are sparse; overseas treatment requires travel. Standard UC pharmacotherapy (biologic agents like infliximab or vedolizumab) costs £3,000–£10,000 annually through private UK insurers, though NHS provides these at no out-of-pocket cost for eligible patients. Stem cell therapy's cost-benefit remains unfavourable in healthcare systems where biologics are accessible, though individual circumstances vary. Out-of-pocket stem cell expenditure may exceed annual pharmaceutical costs within a single treatment cycle.
Am I a candidate? → · Ulcerative Colitis: full overview → · Ulcerative Colitis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite